This Oncology Company’s “Platform In A Pill” Cancer Treatment Could Be A Massive Opportunity

RAS mutations are the initiating genetic events in many cancers – and have proven to be extremely difficult to target. With its lead compound, however, the oncology company featured in today’s article is “looking to become the backbone of treatment for RAS-driven cancers — an opportunity worth more than $20 billion in the U.S. alone.” For more on this company and its “platform in a pill” that could make both investors and patients big winners, CLICK HERE.